Calling all Clinical Phase I Outsourcing Professionals!

Posted:
4
February 2007

Do You Outsource Phase I Clinical Trials?Outsourcing remains a critical aspect of clinical development. All major drug development projects rely on one or more partners to aid the drug development process. The 9th Annual Phase I Clinical Trials conference on 19-20 February at Olympia Conference Centre, London will highlight the following:

  • A timely update on the guidance for first man studies � the revision of EMEA guidelines
  • What are the challenges and priorities over the next five years for the MHRA
  • How to manage potentially 'high risk' complex molecules. Tegenero: a case study
  • The challenges of conducting phase I studies in patients

Get the answers you need to all your outsourcing questions and meet the team from Richmond Pharmacology, the Early Phase CRO that can help you achieve your goals.Wednesday 20 February 2008 at 2pm, Dr. Jörg Täubel MFPM, MD, Managing Director, Richmond Pharmacology, invites you to discuss "Why carry out Phase 1 Trials in the UK, focussing primarily on the regulatory implications of conducting Phase 1 studies in the UK".We look forward to meeting you at the Congress. Visit the Richmond Pharmacology team at Stand No 3 to discuss your Early Phase outsourcing requirements.Exhibitor DiscountAs exhibitors we are delighted to offer you a discount of 25% off the first person and 15% off each additional person after that if you would like to attend the conference. Please call Angela Davie, Business Development Manager, on 020 8664 5200 or book direct quoting our VIP CODE - TT30 and booking code TT30Spex.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more